U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/544,150			
Filing Date	August 1, 2005			
First Named Inventor	Francis X. Smith			
Art Unit	1615			
Examiner Name	AZPURU, Carlos A.			
Attorney Docket Number	3009040 US01			

			U. S. PATEN	F DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (ff known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	^{US-} 5,460,808 A	10-24-1995	Mausner	
		US-			
· · · · · · · · · · · · · · · · · · ·		US-			
		US-			
*		US-			
		US-			

			IGN PATENT DOCL		I n 0-1 1/	7
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T'
	2	WO/1995/000176	01/05/1995	Allergan, Inc.		
				.,.		
						L
						-
						-

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 02/29/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Description of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
Substitut	te 101 101111 1443/1 10			Application Number	10/544,150	
INFO	ORMATION	I DIS	CLOSURE	Filing Date	August 1, 2005	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Francis X. Smith	
	///	4		Art Unit	1615	
	(Use as many sheets as necessary)			Examiner Name	AZPURU, Carlos A.	
Sheet	2	of	2	Attorney Docket Number	3009040 US01	

Evenines	Cito	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials*	Cite No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	GOEBBELS, Martin et al., "Efficacy of Dexpanthenol-containing artificial tears (Siccaprotect) in the treatment of dry eyes", Klinische Monatsblaetter Fuer Augenheilkunde, Vol. 209, no. 2-3, 1996, pages 84-88, XP009106588, ISSN: 0023-2165.	
	4	European Patent Office, European Search Report in European Patent Application No. EP 08 01 4693, Mailed October 17, 2008	
		-	
			2 .

Examiner	Date	
Signature	Considered	

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{**}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.